AL 8697

• Description:

  AL 8697 is a specific and orally active p38α MAPK inhibitor with an IC50 of 6 nM. AL 8697 displays 14-fold greater inhibition of p38α compared to p38β (IC50=82 nM), and 300-fold selectivity for p38α over a panel of 91 kinases. Anti-inflammatory activity[1].

• UNSPSC:

  12352005

• Target:

  Autophagy; p38 MAPK

• Type:

  Reference compound

• Related Pathways:

  Autophagy; MAPK/ERK Pathway

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/al-8697.html

• Purity:

  99.83

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C (NC1CC1) C2=CC (F) =C (C) C (C3=C (F) C4=NN=C (C (C) (C) C) N4C=C3F) =C2

• Molecular Formula:

  C21H21F3N4O

• Molecular Weight:

  402.41

• References & Citations:

  [1]Balagué C, et al. Profiling of dihydroorotate dehydrogenase, p38 and JAK inhibitors in the rat adjuvant-induced arthritis model: a translational study. Br J Pharmacol. 2012 Jun;166 (4) :1320-32.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  P38α; p38β

• CAS Number:

  1057394-06-5